Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention

NCT07156591 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is studying whether people with nerve damage-related stomach emptying problems are more likely to experience delayed stomach emptying while taking the diabetes medication semaglutide.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 460 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2028-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07156591 ↗

Description as written by the study sponsor.

A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted semaglutide therapy

Treatments tested

Esophagogastroduodenoscopy Procedure

Assess the gastric retention during esophagogastroduodenoscopy

Main thing measured	Rate of gastric retention
Sponsor	Fudan University
Conditions studied	Gastric Retention
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07156591 ↗